

**TDMS No.** 20310 - 01

**Test Type:** 26-39 WEEKS

**Route:** GAVAGE

**Species/Strain:**

MICE/C3B6F1-+/Trp53(tm1Brd)

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

3'-Azido-3'-deoxythymidine (AZT)

**CAS Number:** 30516-87-1

**Date Report Requested:** 07/22/2009

**Time Report Requested:** 11:47:38

**First Dose M/F:** NA / 11/18/04

**Lab:** NCTR

**C Number:**

C20310C

**Lock Date:**

12/01/2008

**Cage Range:**

ALL

**Date Range:**

ALL

**Reasons For Removal:**

ALL

**Removal Date Range:**

ALL

**Treatment Groups:**

Include 917 Vehicl PND1-8 F

Include 918 AZT 40 PND1-8 F

**Study Gender:**

Female

**TDMSE Version:**

2.1.0

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle PND1-8 F	AZT 40 PND1-8 F
<b>Disposition Summary</b>		
Animals Initially in Study	26	26
Early Deaths		
Survivors		
Moribund Sacrifice		3
Natural Death	1	
Terminal Sacrifice	25	23
Animals Examined Microscopically	26	26
<b>ALIMENTARY SYSTEM</b>		
Intestine Large, Cecum	(25)	(26)
Hyperplasia, Lymphoid	3 (12%)	
Liver	(25)	(26)
Basophilic Focus		1 (4%)
Infiltration Cellular, Lymphocyte	2 (8%)	1 (4%)
Inflammation, Chronic Active	2 (8%)	
Tension Lipidosis	3 (12%)	4 (15%)
Vacuolization Cytoplasmic	12 (48%)	6 (23%)
Salivary Glands	(25)	(26)
Infiltration Cellular, Lymphocyte	15 (60%)	12 (46%)
<b>CARDIOVASCULAR SYSTEM</b>		
Heart	(25)	(26)
<b>ENDOCRINE SYSTEM</b>		
Adrenal Cortex	(26)	(26)
Subcapsular, Hyperplasia	23 (88%)	24 (92%)
Thyroid Gland	(26)	(26)
Degeneration		1 (4%)
Ectopic Thymus	2 (8%)	1 (4%)
<b>GENERAL BODY SYSTEM</b>		
None		

TDMS No. 20310 - 01  
Test Type: 26-39 WEEKS

Route: GAVAGE  
Species/Strain:  
MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Date Report Requested: 07/22/2009

Time Report Requested: 11:47:38

First Dose M/F: NA / 11/18/04

Lab: NCTR

---

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle PND1-8 F	AZT 40 PND1-8 F
<b>GENITAL SYSTEM</b>		
Ovary	(26)	(26)
Cyst	4 (15%)	1 (4%)
Uterus	(26)	(26)
Infiltration Cellular, Polymorphonuclear	1 (4%)	
Endometrium, Hyperplasia, Cystic	4 (15%)	3 (12%)
Lumen, Dilatation	16 (62%)	13 (50%)
<b>HEMATOPOIETIC SYSTEM</b>		
Bone Marrow	(25)	(26)
Lymph Node	(0)	(2)
Renal, Hyperplasia, Lymphoid		1 (50%)
Lymph Node, Mandibular	(25)	(25)
Hyperplasia, Lymphoid		1 (4%)
Lymph Node, Mesenteric	(25)	(26)
Hyperplasia, Lymphoid	4 (16%)	3 (12%)
Spleen	(26)	(26)
Hematopoietic Cell Proliferation	2 (8%)	2 (8%)
Hyperplasia, Lymphoid	6 (23%)	6 (23%)
Thymus	(25)	(25)
Cyst, Multiple		1 (4%)
Hyperplasia, Lymphoid	1 (4%)	3 (12%)
<b>INTEGUMENTARY SYSTEM</b>		
Mammary Gland	(26)	(26)
<b>MUSCULOSKELETAL SYSTEM</b>		
None		
<b>NERVOUS SYSTEM</b>		
Brain, Brain Stem	(26)	(26)
Brain, Cerebellum	(26)	(26)
Brain, Cerebrum	(26)	(26)
Mineralization	2 (8%)	4 (15%)

---

TDMS No. 20310 - 01  
Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Date Report Requested: 07/22/2009

Time Report Requested: 11:47:38

First Dose M/F: NA / 11/18/04

Lab: NCTR

---

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle PND1-8 F	AZT 40 PND1-8 F
<hr/>		
RESPIRATORY SYSTEM		
Lung	(26)	(26)
Infiltration Cellular, Lymphocyte		1 (4%)
Inflammation, Chronic Active		1 (4%)
<hr/>		
SPECIAL SENSES SYSTEM		
Harderian Gland	(25)	(26)
<hr/>		
URINARY SYSTEM		
Kidney	(25)	(26)
Infiltration Cellular, Lymphocyte	9 (36%)	5 (19%)
Urinary Bladder	(25)	(26)
Infiltration Cellular, Lymphocyte	2 (8%)	3 (12%)
Lumen, Dilatation	1 (4%)	

---

\*\*\* END OF REPORT \*\*\*